NAD IV therapy: the IV NAD+ pharmacokinetics and tolerability research

In plain English

NAD IV therapy means dripping NAD+ (the cell's energy-handling helper molecule) straight into a vein so it skips the gut. Clinics market it; the research behind it is surprisingly thin. The clearest finding is about timing: when NAD+ is infused, the body removes almost all of it from the blood within about two hours ^[5]. These infusions are compounded — mixed to order, not FDA-approved — and one compounded injectable was recalled for contamination ^[5]. This page reports what studies measured. It is not a how-to and recommends no dose.

NAD+ Infusion: Plasma Clearance and Infusion-Rate Tolerability

Intravenous NAD+ infusion is the wellness route with the loudest marketing and the quietest data. The single best-characterized property is pharmacokinetic. A pilot study of an intravenous NAD+ infusion found near-complete removal of NAD+ from plasma within roughly the first two hours of the infusion — the molecule does not linger in the bloodstream ^[5]. A continuous-infusion protocol used in pharmacokinetic work ran at about 3 µmol/min over six hours ^[5]. That rapid clearance is mechanistically unsurprising for a charged dinucleotide and is one reason intravenous protocols are run slowly and over long sessions.

Tolerability is dominated by infusion rate. The discomfort described in connection with IV NAD+ — flushing, chest or abdominal pressure, nausea — is tied to how fast the solution is run and eases when the rate is slowed ^[5]. These are sensations linked to the infusion itself, not evidence of a therapeutic mechanism. Reported clinical infusion protocols span roughly 250 to 1000 mg of NAD+ per session over several hours ^[5], but those are session parameters drawn from practice and small reports, not validated doses, and this digest presents them as study and protocol parameters only.

Does NAD IV actually work in controlled studies?

NAD IV — intravenous NAD+ — has the weakest controlled evidence of any route in this literature. The bulk of intravenous human data come not from NAD+ itself but from its reduced form, NADH, in Parkinson's disease research, and even there the controlled results are unimpressive. In a small double-blind study, five Parkinson's patients given 25 mg NADH intravenously once daily for four days (then intramuscularly at weeks 2 and 4) showed only a non-significant tendency to improve that did not differ from the saline control group, with no change in cerebrospinal-fluid markers ^[7].

Open-label reports look more favorable but lack controls. An open prospective study of 15 idiopathic Parkinson's patients receiving intravenous NADH (10 mg over 30 minutes) for 7 days alongside conventional therapy reported a significant improvement on the Unified Parkinson's Disease Rating Scale and a rise in plasma levodopa availability ^[8]. A larger open-label series of 885 patients — about half intravenous, half oral — reported roughly 80% showing some clinical benefit, with the oral and parenteral routes comparable ^[9]. Open-label, uncontrolled designs cannot separate drug effect from expectation, so the honest reading is that robust efficacy for IV NAD+ is unestablished. For animal mechanism data, intravenous NAD+ at 10-20 mg/kg dose-dependently reduced myocardial infarct size in a rat ischemia/reperfusion model (about 85% reduction at 20 mg/kg) ^[11] — a striking preclinical result that has not been replicated as a human clinical outcome.

The quality and safety picture for infused NAD+

Intravenous NAD+ is a compounded preparation, which means it is mixed by a pharmacy rather than manufactured and approved as a finished drug, and compounding carries documented quality risk. The FDA issued a Class I recall — its most serious category — of a compounded injectable NAD+ product for elevated bacterial endotoxin ^[5]. Endotoxin contamination in an intravenous product is a real hazard, independent of whatever NAD+ does once infused.

A further, theoretical concern applies to any NAD+-raising intervention: because NAD+ supports the metabolism of proliferating cells, boosting it could in principle support existing cancers, and NAD+'s role in oncology is dual and context-dependent ^[5]. None of this is a claim that IV NAD+ is dangerous in a specific case; it is the documented risk profile of an unapproved compounded route with thin efficacy data. Does NAD IV actually work — read the does NAD IV actually work evidence above and weigh it against this safety picture.

Does NAD IV actually work?

IV NAD+ has the weakest controlled evidence of any route. Infused NAD+ is cleared from plasma within about two hours ^[5], and most clinical reports are pilot or retrospective rather than randomized; controlled NADH studies in Parkinson's showed no significant difference from saline ^[7]. The research base does not support strong efficacy claims for intravenous NAD+.

When should you inject NAD+?

There is no validated timing protocol in the peer-reviewed literature. Published parenteral studies used fixed research schedules — for example 25 mg NADH daily for four days ^[7], or 10 mg NADH over 30 minutes for 7 days ^[8] — which are study designs, not dosing instructions. Timing questions are for a qualified clinician, not this digest.